Pharmafile Logo

Divestment

- PMLiVE

GSK pays $85m upfront for Surface Oncology’s lead cancer drug

British pharma company adds preclinical antibody to its pipeline

- PMLiVE

Boehringer spends €1.18bn to acquire NBE-Therapeutics

Company specialises in antibody-drug conjugate development

- PMLiVE

Merck strengthens oncology pipeline with $2.75bn VelosBio deal

The deal will give Merck control of VLS-101, an antibody-drug conjugate

Ongoing Virtual Communication between MSLs and Physicians: a Customer Story

Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians.

Impetus Digital

- PMLiVE

Merck signs separate agreements with Seattle Genetics for two cancer drugs

Merck makes a $1bn equity investment in the biotech company

In the precision medicine era, the line between products and services is blurred

Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?

Blue Latitude Health

- PMLiVE

GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2

Treatment could be transformative for around 260 million people living with disease

- PMLiVE

Novartis’ Sandoz division announces antibiotic manufacturing plan

Joint investment agreed with the Austrian federal government

- PMLiVE

Gilead makes a play for novel cancer drug with Tizona deal

Pharma company continues oncology biotech spending spree

- PMLiVE

Medicago doses first patients with plant-derived COVID-19 vaccine

Study will evaluate candidate alone or in combination with an adjuvant

- PMLiVE

Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs

The five-year deal includes Sitryx’ two lead projects

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links